Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)

INTRODUCTION: Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients. We designed a trial testing tocilizumab versus...

Descripción completa

Detalles Bibliográficos
Autores principales: de Farias, Danielle Leão Cordeiro, Prats, João, Cavalcanti, Alexandre Biasi, Rosa, Regis Goulart, Machado, Flávia Ribeiro, Berwanger, Otávio, de Azevedo, Luciano César Pontes, Lopes, Renato Delascio, Avezum, Álvaro, Kawano-Dourado, Leticia, Damiani, Lucas Petri, Rojas, Salomón Soriano Ordinola, de Oliveira, Cleyton Zanardo, Andrade, Luis Eduardo Coelho, Sandes, Alex Freire, Pintão, Maria Carolina, de Castro Júnior, Claudio Galvão, Scheinberg, Phillip, Veiga, Viviane Cordeiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação de Medicina Intensiva Brasileira - AMIB 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595725/
https://www.ncbi.nlm.nih.gov/pubmed/32965395
http://dx.doi.org/10.5935/0103-507X.20200060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595725/
https://www.ncbi.nlm.nih.gov/pubmed/32965395
http://dx.doi.org/10.5935/0103-507X.20200060

Ejemplares similares